Nicolas Saikali, MD
Neurology · Amherst, NYNPI 1821228511
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,141,615 of the $1,511,501 with a category attached, or 75.5%. 60 manufacturers reported payments, led by AbbVie at 53.2% of the total. Reporting peaked in 2021 at $324,947 and has fallen 56.2% since, to $142,235 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,405 payments — averaging $443.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$804K
- Amgen$195K
- Lundbeck LLC$112K
- Biohaven Pharmaceuticals, Inc.$110K
- Teva Pharmaceuticals USA, Inc.$91K
- Biohaven Pharmaceutical Holding Company Ltd.$57K
- plus $142K from 54 others
Across 34 payments — averaging $4625.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$67K
- AbbVie$46K
- H. Lundbeck A S$34K
- Eli Lilly$10K
- Biohaven Pharmaceutical Holding Company Ltd.$103
Across 7 payments — averaging $20,311 each. An ownership or investment interest held by the physician or an immediate family member.
- Neurology Practice Consortium GPO, LLC$142K
What the payments were for
- Consulting fees$229,00215%
- Speaking & faculty fees$1,141,61576%
- Grants$420%
- Travel & lodging$80,5305%
- Food & beverage$59,6754%
- Education$3380%
- Gifts$3000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,511,501 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 29 | $29,351 |
| UbrelvyUbrogepant | 25 | $27,968 |
| Emgality PenGalcanezumab-Gnlm | 23 | $19,943 |
| Sumatriptan Succinate | 42 | $1,229 |
| Pregabalin | 15 | $1,053 |
| Amitriptyline Hcl | 36 | $585 |
| RizatriptanRizatriptan Benzoate | 28 | $568 |
| Nortriptyline Hcl | 38 | $403 |
| Topiramate | 25 | $254 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $173 |
| Gabapentin | 15 | $120 |
| Tizanidine Hcl | 16 | $86 |
| Cyclobenzaprine Hcl | 13 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $2,623 | $29,35129 claims |
| AbbVieUbrelvy | $804,260 | $27,96825 claims |
| Upsher-smith Laboratories LLCTopiramate | $2,036 | $25425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in Amherst
- Jennifer McVigeAmherst$982K
- Bennett MyersAmherst$432K
- Laszlo MechtlerAmherst$347K
- Wisam ElmalikAmherst$289K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.